In hepatocellular carcinoma, UBE2C downregulation increases the sensitivity to chemotherapeutic agents including doxorubicin, 5-fluorouracil (cellular thymidylate synthase inhibitor), and the multikinase inhibitor sorafenib [70]. This evidence concerns the gene UBE2C and hepatocellular carcinoma.